AstraZeneca: A Global Leader in Pharmaceuticals

AstraZeneca: An Overview

AstraZeneca is a global pharmaceutical company that develops, manufactures, and markets a range of products in various therapeutic areas, including oncology, cardiovascular, renal and metabolism, and respiratory. The company has a presence in over 100 countries and employs approximately 66,000 people worldwide. AstraZeneca is headquartered in Cambridge, UK, and has major operations in Sweden, the United States, and China. AstraZeneca's portfolio of products includes several blockbuster drugs, such as Crestor (rosuvastatin), Nexium (esomeprazole), and Symbicort (budesonide/formoterol). The company also has a strong pipeline of new drugs in development, which are expected to drive future growth.

AstraZeneca's Financial Performance

AstraZeneca has a strong financial performance with revenue of $33.48 billion in 2017, a 15% increase from the previous year. The company's net income was $7.3 billion, a 23% increase from 2016. AstraZeneca's strong financial performance is due to a number of factors, including the success of its blockbuster drugs, the growth of its emerging markets business, and its focus on cost-cutting. The company expects to continue to grow in the future, driven by the launch of new products and the continued growth of its emerging markets business. AstraZeneca has a strong track record of innovation and is well-positioned to continue to develop new and innovative drugs that will improve the lives of patients around the world. The company expects to grow revenue by 5%-10% over the next five years.

AstraZeneca's Research and Development

AstraZeneca is committed to research and development and invests heavily in its pipeline of new drugs. The company has a number of promising drugs in development, including several that are expected to be launched in the next few years. One of AstraZeneca's most promising drugs in development is durvalumab, a monoclonal antibody that inhibits the PD-1 protein. Durvalumab is being developed for the treatment of a variety of cancers, including non-small cell lung cancer, bladder cancer, and triple-negative breast cancer. The drug has shown promising results in clinical trials and is expected to be launched in the United States in 2018. AstraZeneca is also developing a number of other promising drugs, including: * **MEDI3476** a PARP inhibitor for the treatment of ovarian cancer * **AZD9291**, a selective estrogen receptor degrader for the treatment of breast cancer * **AZD2936**, a small molecule for the treatment of chronic obstructive pulmonary disease These drugs are all in late-stage clinical trials and are expected to be launched in the next few years.

AstraZeneca's Social Responsibility

AstraZeneca is committed to social responsibility and has a number of programs in place to give back to the communities in which it operates. The company's social responsibility initiatives include: * **The AstraZeneca HealthCare Foundation**, which provides grants to nonprofit organizations that are working to improve the health of people in developing countries. * **The AstraZeneca Young Health Programme**, which provides educational resources and support to young people who are facing health challenges. * **The AstraZeneca Environmental Sustainability Programme**, which focuses on reducing the company's environmental impact. AstraZeneca is also a member of the United Nations Global Compact, a voluntary initiative that promotes responsible business practices. The company is committed to the Global Compact's ten principles on human rights, labor, environment, and anti-corruption.

AstraZeneca's Future

AstraZeneca is a well-positioned company with a strong track record of innovation and financial performance. The company has a number of promising drugs in development, which are expected to drive future growth. AstraZeneca is also committed to social responsibility and has a number of programs in place to give back to the communities in which it operates. The company is well-positioned to continue to grow in the future and to develop new and innovative drugs that will improve the lives of patients around the world.

Astra Zeneca